Abstract: To provide a power conversion device that is effective for improving controllability of power in power conversion for multilevel voltage output. A power conversion device includes a switching circuit configured to supply a current to a motor by connecting and disconnecting a first point having a first potential, a second point having a second potential greater than the first potential, and a neutral point having a neutral potential between the first potential and the second potential to and from the motor, a neutral potential control unit configured to control the switching circuit in a manner to maintain the neutral potential within a target range, and a current control unit configured to increase a supply current to the motor without affecting a driving force generated by the motor at least when controlling the switching circuit 16 by the neutral potential control unit.

Abstract: A power storage system includes a power storage pack 58 of a power storage device such as a lithium ion secondary battery, supplies electric power to an external load from the power storage device, and charges the power storage device by electric power from outside. The power storage pack 58 is housed in a power storage rack 51 having a top plate 54, a bottom plate 55, and shelf boards 57. A fan case 64 is provided on the power storage rack 51. A ceiling fan 68 is mounted in the fan case 64, and when the ceiling fan 68 is to be attached to the fan case 64 and detached from the fan case 64, the ceiling fan 68 is attached and detached from a front side of an upper surface of the power storage rack 51.

Abstract: A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R3 is a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R4 is a hydrogen atom or a C1-6 alkoxy group; R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.

Abstract: A compound represented by the following formula (I), or salt thereof exhibits excellent CRF receptor antagonism, and sufficient pharmacological activity, safety and pharmacokinetic properties as a drug. wherein R1 represents the formula -A11-A12; R2 represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 1,2-ethylene; A12 represents C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl having methyl; R3 represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R4 represents methoxy or chlorine.

Abstract: A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism.

Abstract: A compound represented by the formula (I) or pharmacologically acceptable salt thereof exhibits an excellent CRF receptor antagonism wherein X is a nitrogen atom or CH; R1 is -A11-A12; A11 is a single bond or a C1-6 alkylene group; A12 is a hydrogen atom, a C1-6 alkyl group or a C3-6 cycloalkyl group, etc.; R2 is -A21-A22; A21 is a single bond or a C1-6 alkylene group; A22 is a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, a non-aromatic heterocyclic group, or a heteroaryl group, etc.; R3 is a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-6 alkoxy group, a C3-6 cycloalkoxy C1-6 alkyl group, di-C1-6 alkyl amino group, a halogen atom, a cyano group, a formyl group, or a carboxyl group, etc; R4 is a hydrogen atom or a C1-6 alkoxy group; R5 is a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group; R6 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, a C1-6 alkylthio group, or a C1-6 alkyl sulfinyl group etc.

Abstract: A compound represented by the following formula (I), or salt thereof exhibits excellent CRF receptor antagonism, and sufficient pharmacological activity, safety and pharmacokinetic properties as a drug. wherein R1 represents the formula -A11-A12; R2 represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 1,2-ethylene; A12 represents C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl having methyl; R3 represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R4 represents methoxy or chlorine.

Abstract: A multiply connected air core coil winding apparatus is provided in which a winding core is protruded and retracted through a first side frame in order to position the winding core between the first side frame and a second side frame, the winding core being rotated when so positioned in order to form a side face of an air core coil. The second side frame is capable of being drawn towards and away from the first side frame. A pocket is provided at one of the side frames for housing the air core coil when the winding material has been completely wound. As a result, multiple air core coils can be wound without cutting the winding material of a first air core coil.

Abstract: This invention relates to a magnetic recording and reproducing device in which automatic settings of optimum recording bias current, optimum recording level and optimum recording equalization characteristic are successively accomplished in this order. The settings of the optimum recording conditions are achieved with high accuracy within short period of time by a computer control using a microprocessor.

Abstract: This invention relates to a magnetic recording and reproducing device in which automatic settings of optimum recording bias current, optimum recording level and optimum recording equalization characteristic are successively accomplished in this order. The settings of the optimum recording conditions are achieved with high accuracy within short period of time by a computer control using a microprocessor.

Abstract: A front-loaded cassette tape deck which moves the cassette a greater relative distance than the distance travelled by the table. A table is normally in the fully projected position because the force provided by a pair of springs is greater than the frictional forces and the damping forces provided by damping pulleys. A cassette is placed in a slider and is held therein by a leaf spring. As the table is moved towards the closed position, the slider is moved by cords and pulleys at a faster rate than the table. Thus, the slider is moved relative to the table. The greater travel of the slider causes it to be moved within a holder by the sliding engagement of a plurality of guide members. During this time, the holder is at an upper position. When the table reaches the closed position, the slider is fully disposed within the holder. The holder with the slider then automatically rotates to a lower position, which puts the cassette into operational engagement with a cassette driving section.